ZEPATIER: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Msd Sub Merck	ZEPATIER	elbasvir; grazoprevir	TABLET;ORAL	208261	NDA	Merck Sharp & Dohme LLC	0006-3074-02	2 DOSE PACK in 1 CARTON (0006-3074-02) / 14 TABLET, FILM COATED in 1 DOSE PACK (0006-3074-01)	2016-01-28
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 28, 2025

Introduction

ZEPATIER, the brand name for the combination drug elbasvir and grazoprevir, is a leading antiviral therapy used primarily to treat chronic hepatitis C virus (HCV) infection. Developed by Merck & Co., ZEPATIER has become a critical component in the global HCV treatment landscape. Its complex formulation and manufacturing process require a robust supply chain involving multiple specialized suppliers. Understanding the key suppliers involved in the production of ZEPATIER offers insights into the drug's market dynamics, supply chain resilience, and potential risks for stakeholders.

Manufacturing Components and Active Pharmaceutical Ingredients (APIs)

The core of ZEPATIER involves two active pharmaceutical ingredients: elbasvir and grazoprevir. The stability, purity, and efficacy of these compounds hinge on high-quality APIs, which are sourced from specialized chemical manufacturers.

Elbasvir API Suppliers

Elbasvir is a non-structural protein 5A (NS5A) inhibitor. Its synthesis necessitates advanced peptide chemistry and complex organic chemistry processes. Several pharmaceutical and chemical companies have been identified as API suppliers:

Hetero Labs Ltd. (India): Historically, Hetero has supplied APIs for various antiviral drugs, including NS5A inhibitors. Their capacity for large-scale synthesis and adherence to GMP standards position them as a significant supplier for elbasvir APIs [1].
Aurobindo Pharma (India): Recognized for its robust API manufacturing infrastructure, Aurobindo has extended its portfolio to include NS5A inhibitors, potentially supplying elbasvir APIs to Merck or its manufacturing partners [2].

Grazoprevir API Suppliers

Grazoprevir, a non-structural protein 3/4A (NS3/4A) protease inhibitor, also demands specialized synthesis pathways:

Mitsubishi Tanabe Pharma Corporation (Japan): Known for its advanced medicinal chemistry capabilities, Mitsubishi has been involved in the development and manufacturing of complex antivirals, positioning it as a potential supplier of grazoprevir APIs [3].
Cipla Ltd. (India): As a leading generic pharmaceutical manufacturer with experience in antiviral APIs, Cipla has the capacity and expertise to supply grazoprevir intermediates or APIs for licenced products [4].

Active Ingredient Synthesis and Specialty Chemical Suppliers

High purity and precise stereochemistry are critical in API synthesis. Most of these chemicals are produced by specialized specialty chemical suppliers:

Salutas Pharma GmbH (Germany): A prominent supplier of pharmaceutical intermediates, involved in API synthesis support, including the production of requisite precursors [5].
Thermo Fisher Scientific (USA): Provides reagents and intermediates crucial for the synthesis process, though not directly supplying APIs, they enable key steps in the manufacturing pipeline [6].

Formulation and Finished Drug Product Manufacturing

Once APIs are produced, the next stage involves formulation into the final dosage form, primarily tablets.

Merck’s Contract Manufacturing Organizations (CMOs): Merck typically contracts with established CMOs for formulation, compression, coating, and packaging. Notable CMOs reported to work on ZEPATIER include:
- Catalent, Inc. (USA): Expert in pharmaceutical compression and coating, ensuring product stability and bioavailability [7].
- Novartis Technical Operations (Switzerland): Provides global manufacturing capabilities, including tablet production for complex antivirals [8].

These partnerships ensure consistent quality and supply of finished ZEPATIER tablets.

Packaging and Distribution

The final steps involve packaging and distribution, often handled by specialized pharmaceutical logistic providers:

UPS Healthcare and DHL Supply Chain: Global leaders in temperature-controlled pharmaceutical logistics, ensuring integrity during distribution [9].
Local distributors in different markets ensure regulatory compliance and timely delivery, vital for maintaining treatment continuity.

Regulatory Inspections and Supplier Compliance

Manufacturing suppliers for ZEPATIER must adhere to stringent Good Manufacturing Practice (GMP) standards. Regulatory agencies like the FDA and EMA routinely audit these suppliers to certify compliance. Suppliers with recent inspections and approvals tend to be preferred, reducing supply chain risks.

Supply Chain Risks and Mitigation Strategies

Dependency on suppliers from regions prone to geopolitical, economic, or natural disruptions presents risks:

Geographic concentration: Heavy reliance on India and China for APIs poses supply continuity concerns due to regulatory changes, trade barriers, or geopolitical tensions [10].
Quality variability: Variations in manufacturing quality can impact drug efficacy and regulatory approval.

Merck mitigates these risks through diversified sourcing, strategic inventories, and qualification of multiple suppliers.

Market Dynamics and Future Trends

The evolving landscape of hepatitis C treatment, driven by the advent of next-generation antivirals and biosimilars, influences supplier engagement:

Increasing pressure for cost reduction prompts Merck and partners to explore APIs from more affordable sources.
Advances in synthetic chemistry and biotechnological production could expand the supplier base, reducing reliance on traditional chemical synthesis.

Conclusion

The supply chain for ZEPATIER involves a complex network of specialized API manufacturers, chemical suppliers, formulation contractors, and logistics providers. Key API suppliers include Hetero Labs, Aurobindo Pharma, Mitsubishi Tanabe Pharma, and Cipla. The strategic diversification and rigorous quality assurance in procurement are essential to overcoming supply risks, ensuring drug availability, and maintaining regulatory compliance. As the hepatitis C treatment landscape evolves, supply chain agility will remain vital for sustaining ZEPATIER’s market position.

Key Takeaways

The supply of ZEPATIER relies heavily on specialized suppliers from India, Japan, and Germany, with dependencies posing potential risks.
API synthesis involves complex chemistry demanding high quality, making supplier qualification, compliance, and diversification critical.
Contract manufacturing organizations play a pivotal role in converting APIs into the final dosage form, with leading players like Catalent contributing to production.
Logistic providers ensure the safe and timely distribution of ZEPATIER, emphasizing the importance of integrated supply chain management.
Future trends point toward increased reliance on advanced synthetic methods and potential diversification of sourcing to mitigate geopolitical and economic risks.

FAQs

1. Who are the primary suppliers of ZEPATIER's active ingredients?
The primary suppliers for elbasvir and grazoprevir APIs include Hetero Labs, Aurobindo Pharma, Mitsubishi Tanabe Pharma, and Cipla, primarily based in India and Japan.

2. What are the main risks associated with the ZEPATIER supply chain?
Risks include geopolitical instability, dependency on suppliers from specific regions, quality variability, and potential manufacturing disruptions.

3. How does Merck ensure quality in its API supply chain?
Merck conducts rigorous supplier qualification, audits, and maintains multiple qualified sources to ensure GMP compliance, quality consistency, and supply reliability.

4. Are there alternatives to current API suppliers for ZEPATIER production?
Yes. Emerging players and new synthetic routes could diversify the supply base, reducing reliance on existing primary suppliers.

5. What role do contract manufacturing organizations play in ZEPATIER production?
CMOs are responsible for formulation, tablet compression, coating, and packaging, ensuring the final product meets quality and regulatory standards.

References

[1] "Hetero Labs: API manufacturing overview." Hetero Group, 2022.
[2] "Aurobindo Pharma's API portfolio." Aurobindo Pharma Annual Report, 2022.
[3] "Mitsubishi Tanabe Pharma: Antiviral research." Mitsubishi Tanabe Pharma Announcements, 2022.
[4] "Cipla Ltd.: Antiviral APIs and formulations." Cipla Annual Report, 2022.
[5] "Salutas Pharma: Pharmaceutical intermediates." Salutas Pharma GmbH, 2022.
[6] "Thermo Fisher Scientific: Reagents and intermediates." Thermo Fisher Scientific, 2022.
[7] "Catalent's role in pharmaceutical manufacturing." Catalent Annual Overview, 2022.
[8] "Novartis technical operations for oral pharmaceuticals." Novartis, 2022.
[9] "Pharmaceutical Logistics Providers." DHL Supply Chain and UPS Healthcare, 2022.
[10] "Global API market trends." IQVIA Market Intelligence Report, 2022.

Suppliers and packagers for ZEPATIER

ZEPATIER

Suppliers for the Pharmaceutical Drug: ZEPATIER